Viking’s VK2735 demonstrates up to 14.7% mean body weight loss after 13 weeks
Patients receiving weekly doses of Viking Therapeutics’ VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and...
top of page
Browse by category
Search
Viking Therapeutics completes of enrolment in VENTURE Trial for GLP-1/GIP receptor agonist VK2735
Viking Therapeutics has completed patient enrolment in its Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of...
GLP-1/GIP candidate VK2735 shows reductions in subjects' liver fat content and plasma lipid levels
Outcomes from Viking Therapeutics’ Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial of VK2735 were...
Viking begins VENTURE trial of dual glp-1/gip receptor agonist VK2735 for obesity
Viking Therapeutics has initiated a Phase 2 clinical trial of VK2735, the company's wholly-owned dual agonist of the glucagon-like...
Viking initiates study to evaluate dual GLP-1/GIP receptor agonist VK2735
Viking Therapeutics has initiated a Phase 1 clinical study to evaluate a novel oral formulation of the company's dual glucagon-like...
Browse by tag
bottom of page